Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: Analysis of the Belgian national database

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 11, 2008, Pages 1113-1122

  van Driel, Mieke L ^a,d   Stichele, Robert Vander ^a   Elseviers, Monique ^c   de Sutter, An ^a,b   de Maesencer, Jan ^a   Christiaens, Thierry ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d BOND UNIVERSITY   (Australia)

Author keywords

Acid suppressants; Evidence based medicine; Guidelines; Health policy; Pharmacoepidemiology; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ARTICLE; BELGIUM; CLINICAL EFFECTIVENESS; COST CONTROL; DATA BASE; DRUG USE; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; NATIONAL HEALTH INSURANCE; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; REIMBURSEMENT; TIME SERIES ANALYSIS; TREND STUDY;

BELGIUM; COST SAVINGS; DRUG COSTS; DRUG UTILIZATION; FINANCING, GOVERNMENT; GUIDELINE ADHERENCE; HEALTH POLICY; HISTAMINE H2 ANTAGONISTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION FEES; PROTON PUMP INHIBITORS; TIME FACTORS;

EID: 57649197949     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1664     Document Type: Article

References (28)

1. Schneeweis S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avorn J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther 2006; 79: 379-388.
2. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003; 349: 2224-2232.
3. Bursey F, Crowley M, Janes C, Turner CJ. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders. CMAJ 2000; 162: 817-823.
4. Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 2002; 166: 1655-1662.
5. RIZIV/INAMI Annual reports [Dutch/French]. Available at: http://riziv.fgov.be/information/nl/statistics/ (Accessed 22 September 2008).
6. http://www.whocc.no/atcddd/ (Accessed 20 July 2007).
7. National Drug Code Directory. Available at: http://www.fda.-gov/cder/ndc/ (Accessed 22 September 2008).
8. Wessling A, Boethius G. Measurement of drug use in a defined population: evaluation of the defined daily dose (DDD) methodology. Eur J Clin Pharmacol 1990; 39: 207-210.
9. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin Pharm Ther 2002; 27: 299-309.
10. RIZIV/INAMI. The rational use of acid suppressant drugs in gastro-oesophageal reflux disease and dyspepsia [Dutch/French]. Report of the consensus conference 15 May 2003. RIZIV/INAMI: Brussels, 2004. Available at: http://riziv.fgov.be/drug/nl/ statistics-scientific-information/consensus/2003-05-15/pdf/lv.pdf (Accessed 22 September 2008).
11. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment, 2004; 8(6). Available at: http://www.ncchta.org/fullmono/momo806.pdf (Accessed 22 September 2008).
12. De Maeseneer JM, van Driel ML, Green LA, van Weel C. Bridging the gap between evidence and patient care: the need for research in primary care. Lancet 2003; 362: 1314-1319.
13. Monnet DL, Ferech M, Frimodt-Moller N, Goossens H. The more antibacterial trade names, the more consumption of antibacterials: a European study. Clin Inf Dis 2005; 41: 114-117.
14. Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med 2005; 118: 881-884.
15. Jones MP. Education, research, and industry. Patients first? J Clin Gastroenterol 2004; 38: 471-474.
16. Klok RM, Boersma C, Oosterhuis I, Visser ST, de Jong-van den Berg LTW, Postma MJ. Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Aliment Pharmacol Ther 2006; 23: 1595-1600.
17. RIZIV/INAMI. Pharmaceutical indicators [Dutch/French]. http://www.riziv.fgov.be/drug/nl/statistics-scientific-information/ pharmanet/pharmaceutical-tables/pdf/2001/guide2001.pdf (Accessed 22 September 2008)
18. NHS Business Services Authority, UK. Prescriptions pricing division. Available at: http://www.ppa.org.uk/index∉flash. htm (Accessed 22 September 2008).
19. The Drug Information System of the Health Care Insurance Board, the Netherlands. Available at: http://www.gipdatabank.nl/ (Accessed 22 September 2008).
20. Vander Stichele RH, Petri H. Utilization patterns of subsidized and nonsubsidized reimbursable peptic ulcer medication in Belgium. Pharmacoepidemiol Drug Saf 1995; 4: 213-224.
21. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 2006; 23: 1587-1593.
22. El Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-333.
23. Malfertheiner P, Fass R, Quigley EMM, et al. Review article: from gastrin to gastro-oesophageal reflux disease-a century of acid suppression. Aliment Pharmacol Ther 2006; 23: 683-690.
24. Agre'us L. Natural history of dyspepsia. Gut 2002; 50 (suppl IV): iv2-iv9.
25. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324: 886-891.
26. Smith R. In search of 'non-disease'. BMJ 2002; 324: 883-885.
27. Teeling M, Bennett K, Freely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Br J Clin Pharmacol 2003; 57: 337-343.
28. Jowell R. Trying It Out: The Role of 'Pilots' in Policy-Making. Cabinet Office: London, 2003.